Bionomics Ltd.


Company Logo

Company Overview

Bionomics (ASX: BNO) (OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of clinical-stage ion channel programs targeting pain, depression, cognition and epilepsy.

Financial Highlights


Revenue (ttm)


Gross Profit (ttm)


Diluted EPS (ttm)

Management Team

Dr. Errol B. De Souza Ph.D.
Exec. Chairman

Mr. Adrian Hinton BEC, F.C.A.
Acting Chief Financial Officer

Mr. Connor Bernstein M.Sc.
VP of Strategy & Corp. Devel.

Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.
Consultant Chief Medical Officer of Clinical Neuroscience

Ms. Suzanne Irwin B.Com., FCIS
Company Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile




Key Highlights

Market Capitalization

Shares Outstanding

Shares Short (% of Float)

Insider Ownership